Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

This study has been completed.
Progen Pharmaceuticals
Information provided by (Responsible Party):
Medigen Biotechnology Corporation Identifier:
First received: August 12, 2005
Last updated: March 30, 2016
Last verified: March 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2010
  Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)